Edison Investment Research - Sequana Medical (SEQUA) Sequana Medical - New CPT III codes to support reimbursement

Report

Edison Investment Research

Sean Conroy

Sequana Medical - New CPT III codes to support reimbursement

Sequana Medical announced that the American Medical Association has issued six new Category III Current Procedural Terminology (CPT III) codes for the alfapump system. The issue of these codes augments the existing ICD-10 procedure codes and is expected to assist healthcare professionals and insurers in identifying specific procedures related to the alfapump system for reimbursement. This may broaden and facilitate the future US utilisation and reimbursement for the alfapump for the treatment of recurrent and refractory ascites (RRA) on regulatory approval. Sequana had submitted a Premarket Approval application to the US FDA on 27 December for the alfapump device and we remain confident that there is a high likelihood of a positive regulatory approval decision in H224, given the robust efficacy data from the POSEIDON North American pivotal study.

05/01/2024 1 EN

Underlying

Sequana Medical

Sequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

See profile

BE0974340722 Euronext Brussels Belgium

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

KBC Securities

Morning Notes : SEQUA BB

: SEQUA BB

April 3, 2024 April 3, 2024 1 EN

KBC Securities

Morning Notes : AED BB, BFIT NA, EURN BB, HAL NA, IVA FP, MITRA BB, SEQUA BB, TESB BB, AZE BB, FAST NA

: AED BB, BFIT NA, EURN BB, HAL NA, IVA FP, MITRA BB, SEQUA BB, TESB BB, AZE BB, FAST NA

March 28, 2024 March 28, 2024 1 EN

KBC Securities

Sequana Medical FIRST LOOK: FY23 update comes with 90-day FDA letter for alfapump PMA

Sequana reported FY23 results with a cash position of € 2.6m (YE22: € 18.9m), which together with the € 3m convertible loan in February 2024 and € 11.5m equity placement in March 2024, provides a cash runway to end of 3Q24. The company is evaluating the feedback received last night in the 90-day letter from the FDA. Given the short timeframe, management is unable to provide more details on the FDA comments, and will update the market in due course. The company has a day-100 meeting scheduled with the FDA on 9 April 2024, and we expect a more detailed update on timelines subsequently. For now, ...

March 28, 2024 March 28, 2024 1 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

May 17, 2024 May 17, 2024 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

May 17, 2024 May 17, 2024 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Sequana Medical - New CPT III codes to support reimbursement

Morning Notes : SEQUA BB

Morning Notes : AED BB, BFIT NA, EURN BB, HAL NA, IVA FP, MITRA BB, SEQUA BB, TESB BB, AZE BB, FAST NA

Sequana Medical FIRST LOOK: FY23 update comes with 90-day FDA letter for alfapump PMA

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

AAC Clyde Space - Solid start to the year with further order growth

Tinexta - Typical seasonality in Q124

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe